Evaxion Biotech (EVAX) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 7:30 AM EDTReceived regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving first doseAnnounced publication on personalized therapy with EVX-01 in patients with metastatic melanoma in the open-access, peer-reviewed medical science journal OncoImmunologyHosted Key Opinion Leader (KOL) webinar with acclaimed experts on metastatic melanoma and personalized cancer immunotherapiesEnded first quarter with cash and cash equivalents of $31.4 millionEvaxion will host webcast and conference call today, May 11, at 8:30 am EDT
COPENHAGEN, Denmark, May... More
